Ventripoint Diagnostics Stock Performance
| VPTDF Stock | USD 0.10 0.01 9.09% |
The entity has a beta of 0.37, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, VentriPoint Diagnostics' returns are expected to increase less than the market. However, during the bear market, the loss of holding VentriPoint Diagnostics is expected to be smaller as well. At this point, VentriPoint Diagnostics has a negative expected return of -0.31%. Please make sure to validate VentriPoint Diagnostics' skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if VentriPoint Diagnostics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days VentriPoint Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's fundamental indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 526 K |
VentriPoint |
VentriPoint Diagnostics Relative Risk vs. Return Landscape
If you would invest 14.00 in VentriPoint Diagnostics on August 28, 2024 and sell it today you would lose (4.00) from holding VentriPoint Diagnostics or give up 28.57% of portfolio value over 90 days. VentriPoint Diagnostics is currently producing negative expected returns and takes up 6.6804% volatility of returns over 90 trading days. Put another way, 59% of traded otc stocks are less volatile than VentriPoint, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
VentriPoint Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for VentriPoint Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as VentriPoint Diagnostics, and traders can use it to determine the average amount a VentriPoint Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0463
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VPTDF |
Estimated Market Risk
| 6.68 actual daily | 59 59% of assets are less volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average VentriPoint Diagnostics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VentriPoint Diagnostics by adding VentriPoint Diagnostics to a well-diversified portfolio.
VentriPoint Diagnostics Fundamentals Growth
VentriPoint OTC Stock prices reflect investors' perceptions of the future prospects and financial health of VentriPoint Diagnostics, and VentriPoint Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VentriPoint OTC Stock performance.
| Return On Equity | -1.35 | |||
| Return On Asset | -0.64 | |||
| Operating Margin | (124.50) % | |||
| Current Valuation | 28.27 M | |||
| Shares Outstanding | 156.51 M | |||
| Price To Earning | 68.00 X | |||
| Price To Book | 8.27 X | |||
| Price To Sales | 897.04 X | |||
| EBITDA | (3.82 M) | |||
| Cash And Equivalents | 7.29 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 125.38 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (3.15 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 9.54 M | |||
| Retained Earnings | (20.43 M) | |||
| Current Asset | 1.07 M | |||
| Current Liabilities | 3.05 M | |||
About VentriPoint Diagnostics Performance
By analyzing VentriPoint Diagnostics' fundamental ratios, stakeholders can gain valuable insights into VentriPoint Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if VentriPoint Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if VentriPoint Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company was incorporated in 2004 and is based in Toronto, Canada. Ventripoint Diagnostics is traded on OTC Exchange in the United States.Things to note about VentriPoint Diagnostics performance evaluation
Checking the ongoing alerts about VentriPoint Diagnostics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for VentriPoint Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| VentriPoint Diagnostics generated a negative expected return over the last 90 days | |
| VentriPoint Diagnostics has high historical volatility and very poor performance | |
| VentriPoint Diagnostics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (3.88 M) with loss before overhead, payroll, taxes, and interest of (6.27 K). | |
| VentriPoint Diagnostics has accumulated about 7.29 M in cash with (3.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. |
- Analyzing VentriPoint Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether VentriPoint Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining VentriPoint Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating VentriPoint Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of VentriPoint Diagnostics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of VentriPoint Diagnostics' otc stock. These opinions can provide insight into VentriPoint Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for VentriPoint OTC Stock analysis
When running VentriPoint Diagnostics' price analysis, check to measure VentriPoint Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VentriPoint Diagnostics is operating at the current time. Most of VentriPoint Diagnostics' value examination focuses on studying past and present price action to predict the probability of VentriPoint Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VentriPoint Diagnostics' price. Additionally, you may evaluate how the addition of VentriPoint Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |